Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype- Breast Cancer.

Conclusion: Despite the low pCR rate, the tumor response and BCS conversion rates after NAC of luminal HER2- breast cancer were similar to those of other subtypes. NAC has the potential benefit of reducing the size of breast cancer, thereby increasing the BCS conversion rate in luminal HER2- breast cancer. PMID: 31598341 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31598341?dopt=Abstract

Source: Journal of Breast Cancer - October 12, 2019 Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research